Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2012
At a glance
- Drugs TPI 1020 (Primary) ; Budesonide
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2009 Company (Pharmaxis) added to the associations field as reported by as reported by ClinicalTrials.gov.
- 04 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 23 Dec 2008 Results reported in a Topigen Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History